Cargando…
Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency
INTRODUCTION: Continuous infusion (CI) of clotting factors as a replacement therapy for perioperative hemostatic protection has been performed for many years, including with factors VIII and IX and recombinant activated factor VII (rFVIIa). This approach provides steady factor levels without requiri...
Autores principales: | Rajpurkar, Madhvi, Cooper, David L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276614/ https://www.ncbi.nlm.nih.gov/pubmed/30568523 http://dx.doi.org/10.2147/JBM.S184040 |
Ejemplares similares
-
Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®))
por: Bartosh, Nicole S, et al.
Publicado: (2013) -
Psychosocial Impact and Disease Management in Patients with Congenital Factor VII Deficiency
por: Peltier, Skye, et al.
Publicado: (2020) -
Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors
por: Chuansumrit, Ampaiwan, et al.
Publicado: (2010) -
Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
por: Johansson, Pär I, et al.
Publicado: (2010) -
Recombinant activated factor VII administration in a patient with congenital lack of factor VII undergoing laparoscopic hysterectomy: A case report
por: Dąbrowski, Filip A., et al.
Publicado: (2021)